GlassScriptPhysician profile
Adam J Crowson
NPI 1225635329
$4,435.65
in general payments reported to CMS, 2019-2025
32 companies · $875 in 2025
The $875 reported for 2025 was more than what 78% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $448 · 2022: $474 · 2023: $1,370 · 2024: $1,270 · 2025: $875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,514.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $917.66 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $434.08 | 2021-2025 | Repatha, Otezla, Prolia |
| Lilly USA, LLC | $400.32 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $297.92 | 2021-2025 | Farxiga, Airsupra |
| Abbvie INC. | $250.11 | 2023-2025 | |
| Glaxosmithkline, LLC. | $232.62 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $221.68 | 2023-2025 | |
| Dexcom, INC. | $214.29 | 2023-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $161.41 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Atricure, INC. | $148.80 | 2021 | |
| Boston Scientific Corporation | $116.86 | 2022 | |
| Mannkind Corporation | $109.14 | 2022 | |
| Novartis Pharmaceuticals Corporation | $102.46 | 2022-2025 | |
| Axsome Therapeutics, INC. | $101.35 | 2023-2025 | Auvelity, Symbravo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.17 | 2023-2025 | Xifaxan, Trulance |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $71.98 | 2025 | Carto 3 |
| Corcept Therapeutics | $65.44 | 2024-2025 | Korlym |
| Insulet Corporation | $64.47 | 2023-2024 | Omnipod |
| Idorsia Pharmaceuticals US INC | $63.33 | 2023 | Quviviq |
| Nevro Corp. | $62.00 | 2023 | Senza |
| Sanofi-Aventis U.S. LLC | $61.74 | 2023 | |
| Phathom Pharmaceuticals, INC. | $35.87 | 2024 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.66 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $29.47 | 2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $27.24 | 2023 | Gvoke Hypopen |
| Grt US Holding, INC. | $26.32 | 2021 | |
| Lundbeck LLC | $17.98 | 2023 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $16.44 | 2023 | Livalo |
| Tris Pharma INC | $16.12 | 2025 | Dyanavel Xr |
| Eisai INC. | $15.46 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.67 | 2023 | |
| Genentech USA, INC. | $10.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Crowson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.